

# 1 **Alteration of serum leptin and LEP/LEPR promoter methylation in Prader-Willi** 2 **syndrome**

3

4 Jelte Wieting *a\**, Kirsten Jahn *a\**, Vanessa Buchholz *a*, Ralf Lichtinghagen *b*, Stefan Bleich *a*,  
5 Christian K. Eberlein *a*, Maximilian Deest *a\**, Helge Frieling *a\**

6

7 *a* Hannover Medical School, Department for Psychiatry, Social Psychiatry and Psychotherapy, Carl-Neuberg-Str. 1, 30626,  
8 Hannover, Germany

9 *b* Hannover Medical School, Department for Clinical Chemistry, Carl-Neuberg-Str. 1, 30626, Hannover, Germany

10

11 \* JW and KJ should be considered joint first author. MD and HF should be considered joint senior author.

12

13 Corresponding Author: Dr. med. Jelte Wieting, Hannover Medical School, Department for Psychiatry, Social Psychiatry and  
14 Psychotherapy, Carl-Neuberg-Str. 1, 30626, Hannover, Germany; [mailto: wieting.jelte@mh-hannover.de](mailto:wieting.jelte@mh-hannover.de), phone  
15 +4917615328338

16

## 17 **ABSTRACT**

18 Prader-Willi syndrome (PWS) is a rare neurodevelopmental disorder based on a loss of paternally expressed  
19 but maternally imprinted genes in chromosome region 15q11-13. During child development, PWS usually  
20 results in insatiable appetite with subsequent obesity representing the major mortality factor. The  
21 neurobiological basis of PWS-typical hyperphagia has remained poorly understood. Many PWS-typical  
22 abnormalities are based on hypothalamic dysregulation, the region in which hunger and satiety are hormonally  
23 regulated, with the hormone leptin being a main long-term regulator of satiety. Previous studies in PWS have  
24 inconsistently shown leptin alterations solely in early childhood, without investigating the leptin system on an  
25 epigenetic level.

26 The present study investigates serum leptin levels (S-leptin) and methylation of the leptin (LEP) and leptin  
27 receptor gene (LEPR) promoter in 24 individuals with PWS compared to 13 healthy controls matched for sex,  
28 age, and body mass index (BMI) and relates the results to the extent of hyperphagia in PWS.

29 S-Leptin levels were obtained by Enzyme-linked Immunosorbent Assay. LEP/LEPR-promoter methylation was  
30 assessed by DNA-bisulfite-sequencing, hyperphagia by Hyperphagia Questionnaire for Clinical Trials (HQ-CT).  
31 PWS and control groups differed significantly in S-leptin levels with higher S-leptin in PWS. Methylation analysis  
32 showed significant differences in mean promoter methylation rate both for LEP and LEPR with a lower  
33 methylation rate in PWS. LEPR, but not LEP methylation correlated with S-leptin levels. S-leptin and both LEP  
34 and LEPR methylation did not correlate with HQ-CT scores in PWS.  
35 The present study is the first to show significantly elevated S-leptin levels in an adult PWS cohort combined  
36 with an altered, downregulated LEP and LEPR promoter methylation status compared to BMI-matched  
37 controls. Analogous to previous studies, no link to the behavioral dimension could be drawn. Overall, the  
38 results suggest an increased leptin dysregulation in PWS, whereby the findings partly mirror leptin resistance  
39 seen in non-syndromic obesity.

40

#### 41 **INTRODUCTION**

42 Prader-Willi syndrome (PWS) is a rare neuronal developmental disorders with an estimated prevalence of  
43 1:15000 (1). The syndrome is genetically determined by a loss of normally paternally expressed but maternally  
44 imprinted genes on chromosome 15q11-13. Essentially, three different genetic subtypes can lead to PWS. Most  
45 common, in about 70% of cases, is a large deletion of the paternal allele of chr15q11-13 (delPWS). In about 25-  
46 30% of cases a maternal uniparental disomy of chromosome 15 (UPD) and in rare cases, a defect of the  
47 imprinting center (IC) occurs (2).

48 Newborns initially present with a failure to thrive and muscular hypotension. During infancy, PWS individuals  
49 rapidly develop an insatiable appetite leading to massive weight gain unless food intake is regulated.  
50 Individuals with PWS show a deficiency of growth hormones and hypogonadism, accompanied by a  
51 dysregulation of body temperature and altered pain tolerance, which can essentially be explained by  
52 hypothalamic dysfunction (3). In addition, in almost all cases there is a mild to moderate intellectual  
53 impairment as well as an overall delay in language and motor development. But also, individuals with PWS  
54 exhibit a certain behavioral phenotype characterized by temper outbursts, repetitive and ritualistic behaviors,  
55 and skin-picking(4). Despite improved diagnostics and therapy, life expectancy is still assumed to be reduced in  
56 people with PWS. Obesity and its sequelae such as cardiovascular diseases, diabetes, as well as sleep apnea and  
57 other respiratory complications are the major driving factor for the increased mortality rate in people with PWS

58 (5). Therefore, basic research into the causes of hyperphagia and obesity in PWS is of particular importance for  
59 improved diagnosis and treatment.

60

61 In human, satiety is induced essentially via stimulation of melanocortin-4 receptors (MCR-4) by the  
62 proopiomelanocortin (POMC) derivative alpha- melanocyte stimulating hormone (alpha-MSH) in the  
63 paraventricular nucleus of the hypothalamus. Besides stimulation of POMC, leptin inhibits AgRP- and  
64 neuropeptide Y (NPY)-producing neurons in the arcuate nucleus of hypothalamus, hormones, which have an  
65 appetite-increasing effect via MCR-4 inhibition. Leptin has an appetite suppressing, energy expenditure  
66 increasing and consequently body weight reducing effect (6). Animal studies suggest that leptin receptors are  
67 also found in the ventral tegmental and other midbrain areas, in which the regulation of the endogenous  
68 reward system is mediated (7).

69 In humans, the hormone leptin is encoded on the LEP gene located on chromosome 7q31.3 and composed of  
70 three exons and two introns. It is largely expressed in adipocytes, but also to a lesser extent centrally in the  
71 hypothalamus and pituitary gland, as well as other tissues (8). The physiological regulatory mechanisms behind  
72 leptin expression are complex. In healthy individuals, leptin blood levels correlate with body fat stores (9). In  
73 women, circulating leptin is significantly elevated compared to men. With increasing age leptin levels decrease  
74 (10). Fasting causes a decrease in leptin levels in humans, whereas levels re-increase after days of refeeding  
75 (11). It is important to note that leptin levels do not increase in response to individual meals (12). Leptin can be  
76 considered as a long-term indicator of the body's energy reserves.

77 Leptin exerts its effect via leptin receptors. The LEPR gene is located on chromosome 1 (1p31) and consists of  
78 18 exons and 17 introns. One of the splice variants of the LEPR gene, the longest isoform LEPRb is most widely  
79 expressed in the human brain, particularly in the hypothalamus and cerebellum, although leptin receptors are  
80 also expressed in other tissues such as the vasculature and stomach. Only the long isoform LepRb contains the  
81 intracellular motif required for leptin-mediated POMC-activation in the hypothalamus, making this isoform the  
82 main mediator of the above-mentioned leptin-specific effects (13).

83 Due to its size, leptin is unable to cross the blood-brain barrier (BBB) by diffusion. The neurobiological  
84 mechanisms of transporting leptin across the BBB are mainly unclear. In obese individuals, elevated leptin  
85 levels continue to be seen in both blood and adipocytes, but no significant leptin effect can be discerned.  
86 Accordingly, leptin resistance in obesity is assumed. Most of the evidence on the cellular and molecular

87 mechanisms of leptin resistance has been obtained in experimental rodent models. Obese mice showed  
88 resistance to peripherally administered leptin but responded to intracerebroventricular infusions of leptin. The  
89 efficiency of central leptin uptake measured as CSF/plasma leptin ratio was 4.3-fold higher in lean than in  
90 obese subjects indicating a dysregulated leptin transport across the BBB to be associated with leptin resistance.

91

92 The causes for obesity in PWS are currently understood in rudimentary terms at best. Misbalances in the  
93 abovementioned hypothalamic satiety center and the various hormones influencing it have been suspected  
94 with the hyperphagia typical of PWS. Regarding leptin, significant differences in blood levels compared with  
95 obese controls have so far only been demonstrated for young children with PWS. Previous studies showed  
96 significantly higher leptin levels in infants <6 years of age compared to weight-matched controls in collectives  
97 sized 42 PWS to nine control (14) and 33 PWS to 28 control subjects (15), whereas this finding was absent in  
98 children >6 years of age in a study sized 35 PWS (n=21 <6y, n=14 >6y) and 31 age and BMI-matched controls  
99 (16). 22 adult patients with PWS showed elevated blood leptin levels compared to 54 healthy controls (17), but  
100 in adult PWS there were no significant differences compared to weight-adapted control subjects in cohorts of  
101 20 PWS to 14 control (18) and 28 PWS to 29 obese control subjects (19). An older study by Butler et al. also  
102 showed no relevant differences between PWS and BMI-matched controls (PWS n=19 obese and n=14 non-  
103 obese, controls n=28 obese and n=16 non-obese), with the exception that non-overweight male PWS subjects  
104 had five times higher plasma leptin levels than controls (20). On a genetic level, Lindgren et al. examined leptin  
105 mRNA levels in subcutaneous adipose tissue in comparison of healthy controls and PWS children on the one  
106 hand and non-syndromic obesity on the other. Leptin mRNA levels were found to be significantly increased in  
107 both PWS and non-syndromic obese controls compared with healthy subjects, but there was no significant  
108 difference between PWS and non-syndromic obese controls. Both leptin serum and leptin mRNA levels  
109 correlated with BMI in PWS. However, the results are clearly limited by the small number of cases (n=6 each)  
110 (21).

111

112 Preliminary studies illuminated the influence of epigenetic mechanisms on hormone balance, including leptin,  
113 which is investigated in the present work. One important epigenetic mechanism is the methylation of cytosine  
114 bases in the DNA strand, which occurs only in the context of cytosine-guanine dinucleotides (CpGs).  
115 Methylation of the gene promoter is of particular interest in that it represents an essential regulatory unit for

116 gene expression. Among other mechanisms, increased methylation impedes the binding of transcription factors  
117 so that protein biosynthesis is subsequently suppressed (22).

118 In the context of metabolic diseases, research results are available from both animal and human studies  
119 regarding altered LEP methylation status and leptin expression. In human studies, an association between  
120 decreased LEP-methylation status and obesity has been demonstrated in male children (23). In obese  
121 adolescents, a decreased methylation status of the LEP promoter region was detected in peripheral blood (24).

122 Overall, the data predominantly indicate hypomethylation of the LEP promoter region in metabolic disorders.  
123 In general, an inverse correlation between LEP promoter methylation and leptin expression is assumed (25).

124 In our previous publication on the subject, we examined 98 obese patients before and after bariatric surgery  
125 with respect to LEP promoter methylation and leptin expression. Consistent with previous studies, we saw  
126 increased leptin serum levels before bariatric surgery. But in contrast to the majority of studies regarding LEP  
127 promoter methylation, we found an increased LEP promoter methylation before surgery compared with  
128 postoperative levels (26).

129 Alterations of the LEPR gene in obesity have been less studied overall. In the aforementioned study on bariatric  
130 surgery, there was an increased postoperative LEPR methylation accompanied by an inverse association  
131 between LEPR methylation and S-leptin levels. Furthermore, another study on the influence of pre-pregnancy  
132 BMI on gestational weight suggested an inverse correlation between LEPR methylation and LepRb expression  
133 (27).

134

135 In the present study, we investigate the leptin system in an adult PWS collective compared to healthy BMI-  
136 matched controls. For the first time, we assess the regulatory level in terms of LEP and LEPR promoter  
137 methylation in PWS. The results will be related to the extent of hyperphagia the PWS subjects undergo, which  
138 is assessed by a specific questionnaire.

139

## 140 **METHODS**

### 141 **STUDY CHARACTERISTICS**

142 The study included 24 subjects with PWS (14 male, 10 female) and 13 healthy control subjects (8 male, 5  
143 female) matched for sex, age, and body mass index (BMI). Control subjects with a difference of +/- 5 years and  
144 +/- 1 kg/m<sup>2</sup> BMI compared to the study cohort were considered. The control subjects were recruited via public

145 tenders analogously and online. The healthy control subjects confirmed during the interview that they had not  
146 been diagnosed with any mental illness at the time of the study. The participants of this study are part of a  
147 larger register study entitled PSY-PWS which takes place at Hannover Medical School and is described in more  
148 detail in former publications (28,29). The study followed the Declaration of Helsinki and was reviewed and  
149 approved by the local ethics committee of Hannover Medical School (No: 8129\_BO\_S\_2020). All subjects or  
150 their legal representatives gave written informed consent to participation after all study procedures were  
151 explained to them.

152

153 The HQ-CT (Hyperphagia Questionnaire for Clinical Trials) in German language was used to assess the level of  
154 hyperphagia-related behavior in PWS. The HQ-CT is specifically designed and validated for PWS. It is a 9-item  
155 caregiver-report test instrument considered to be the current gold standard for hyperphagia assessment in  
156 PWS. The HQ-CT total score results from the sum of the 9 item-level responses ranging from 0 to 4 with a  
157 maximum score of 36 (30). Cut-off values above which clinically significant symptoms can be assumed have not  
158 yet been established.

159

#### 160 MOLECULAR ANALYSIS

161 DNA was extracted from blood samples using chemagicStar DNA-Blood1k kit (PerkinElmer Chemagen  
162 Technology, Baesweiler, Germany). The genomic DNA was subsequently bisulfite converted using the EpiTect®  
163 96 Bisulfite Kit (Qiagen, Hilden, Germany) to detect the methylation status of the cytosine bases. Our target  
164 sequences within the LEP and LEPR promoter region were amplified from the previously purified bisulfite-  
165 converted DNA by polymerase chain reaction. Primers were designed to cover a LEP fragment of 823 bp (Hg 38,  
166 Chr. 7: 128.240.657 to 128.241.478), including exon 1 (Hg 38, Chr.7: 128.241.277 to 128.241.306), with 65 CpG-  
167 sites covered, and a LEPR fragment of 461 bp length (Hg 38, Chr. 1: 65.420.416 to 65.420.876), including exon 1  
168 (Hg 38, Chr. 1: 65.420.651 to 65.420.741). The number of covered CpG-sites was 46.

169 Sequencing was performed using the Big-Dye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems,  
170 Foster City, CA, USA). Individual PCR protocols and primer sequences can be found in **Supplementary Material**  
171 **S1**.

172

173 To determine the methylation status of the different CpG loci from the data obtained by DNA sequencing,  
174 Epigenetic Sequencing Methylation Analysis Software (ESME) was used (31). Methylation for each CpG site was  
175 calculated per each subject by building the ratio between normalized peak values of cytosine and thymine.

176

177 S-leptin levels were determined by enzyme-linked immunosorbent assay (ELISA) from Serum blood samples  
178 using Quantikine® Human Leptin Immunoassay (R&D Systems, Minneapolis, MN, USA).

179

180 STATISTICS

181 Sequence Scanner v2.0 software (ABI Life Technologies, Grand Island, NY, USA) was used for sequence quality  
182 control. Only sequences showing a QV (quality value) > 20 were included for further analysis.

183 For statistical analysis, we used SPSS (IBM, Armonk, NY, USA). For graphical data processing, Graph Pad Prism  
184 (GraphPad, LaJolla, CA, USA) was used.

185 Data were further checked for missing values and variance. Single CpGs with more than 5% missing values and  
186 inter-individual variability below 5% were removed from the analysis. In addition, subjects with more than 5%  
187 missing values in methylation rate were excluded (see **Supplementary Material S2**).

188

189 Mann-Whitney test was used to compare differences in S-leptin levels and BMI between PWS and control  
190 subjects. We calculated mixed linear models to detect fixed effects of the variable group (PWS or control), CpG-  
191 position, sex and BMI on methylation rate. BMI and age were set as parameters of covariance. Bonferroni  
192 correction was applied to correct p-values for multiple testing. Differences in methylation rates at individual  
193 CpG sites were assessed within the mixed linear model with data splitted for CpG site. Fixed effects of factor  
194 group were calculated for the individual CpG sites. p values of < 0.05 were considered significant.

195

196 To assess the correlation between HQ-CT and the LEP/LEPR methylation in total and for individual CpG sites  
197 Pearson's correlation coefficient was calculated. In addition, two groups were derived from the HQ-CT scores,  
198 with one group below and another group equal to or above the surveyed median HQ score of 8 in the PWS  
199 group for comparing LEP/LEPR methylation in pronounced hyperphagia with less pronounced hyperphagia. To  
200 this end, we examined effects of the factor “clinical severity of hyperphagia” on methylation rate according to  
201 the MLM detailed above and made group-wise comparisons.

202

## 203 RESULTS

### 204 PATIENT CHARACTERISTICS

205 The study included 24 subjects with Prader-Willi syndrome (male n=14, 58.3%; female n=10, 41.7%) and 13  
206 healthy control subjects (male n=8, 61.5%; female n=5, 38.5%). In PWS subjects, the mean age was 27 years  
207 (minimum 12y, maximum 55y), whereas in controls, the mean age was 32 years (minimum 18y, maximum 47y).  
208 As matched for this, BMI values differed only slightly between groups showing no significant difference  
209 according to Mann Whitney test,  $U = 166$ ,  $Z = 0.318$ ,  $p = 0.766$ . Mean BMI was  $27.2 \text{ kg/m}^2$  in PWS (Minimum  
210  $19.1 \text{ kg/m}^2$ , Maximum  $39.1 \text{ kg/m}^2$ ) and  $26.6 \text{ kg/m}^2$  in healthy controls (Minimum  $19.4 \text{ kg/m}^2$ , Maximum  $40.0$   
211  $\text{kg/m}^2$ ). Genetic subtype was determined in all subjects with PWS. DelPWS (n=11) and UPD (n=7) were shown  
212 most frequently (UPD/IC n=4 and IC n=2). Mean HQ-RT score in the PWS group was 10.39 (median 8, minimum  
213 1, maximum 33).

214 **Table 1** presents the patient characteristics in detail.

215

### 216 S-LEPTIN

217 Mean S-Leptin in PWS subjects was  $32.747 \text{ ng/ml}$  (Minimum  $3.261 \text{ ng/ml}$ , Maximum  $79.822 \text{ ng/ml}$ ) and  $11.928$   
218  $\text{ng/ml}$  in control group (Minimum  $0.116 \text{ ng/ml}$ , Maximum  $43.797 \text{ ng/ml}$ ). Divided by sex, female subjects had  
219 higher serum leptin levels than males in both the PWS and control groups. Male PWS had a mean leptin level of  
220  $26,608 \text{ ng/ml}$  (min  $3,261$ , max  $79,822$ ), female of  $41,316 \text{ ng/ml}$  (min  $14,755$ , max  $68,826$ ). Controls also showed  
221 a difference between males with an average of  $5.324 \text{ ng/ml}$  (Min  $0.116$ , Max  $16.213$ ) to  $22.493 \text{ ng/ml}$  (Min  
222  $7.068$ , Max  $43.797$ ) in female controls.

223 According to Mann Whitney test for comparison of PWS and control groups in terms of S-leptin levels there  
224 was a significant difference between the groups,  $U = 245.00$ ,  $Z = 2.831$ ,  $p = 0.004$  (see **Table 1** and **Figure 1**).

225 Serum leptin levels correlate highly positively with BMI in both PWS subjects (linear  $R^2 = 0.502$ ) and healthy  
226 control subjects (linear  $R^2 = 0.623$ ). S-Leptin values do not correlate with the HQ results in the PWS subjects  
227 (linear  $R^2 = 0.016$ ).

228

### 229 LEP METHYLATION



230 For LEP significant fixed effects on methylation rate of individual CpG position ( $F_{(48,1660)} = 85,312$ ;  $p < 0.001$ ) and  
231 group ( $F_{(1,1660)} = 22,706$ ,  $p < 0.001$ ) were detected. MLM revealed no significant CpG x group interaction for LEP  
232 gene ( $F_{(48,1660)} = 1,247$ ;  $p = 0,121$ ). We found independent effects of age ( $F_{(1,1660)} = 34,185$ ;  $p < 0,001$ ), but not  
233 of sex ( $F_{(1,1660)} = 2,657$ ,  $p = 0,103$ ) nor BMI ( $F_{(1,1660)} = 1,52$ ,  $p = 0,218$ ). Significance of group differences was not  
234 affected when age and gender were applied as additional factors.

235 Overall LEP mean methylation rate was shown to be lower in PWS (29.9%) compared to healthy controls  
236 (32,5%) (see **Figure 2**). Analysis of fixed effects of factor group on single CpG sites methylation revealed  
237 significant effects for eleven individual CpG positions (m169, m199, m203, m329, m331, m338, m340, m349,  
238 m371, m373 and m378). All CpG sites named above showed a significantly lower mean methylation rate in the  
239 PWS group compared to controls. The CpG positions m329 and m331, m338 and m340, and m349 to m373  
240 sequentially follow each other in the base sequence. **Figure 3** shows a graphical representation of these results.  
241 No significant differences in mean methylation rate were found between the sexes with males showing an  
242 insignificantly higher methylation rate (31,6%) compared to females (30,8%). For detailed statistical results see  
243 **Supplementary Material S3**.

244 Correlation analysis revealed no significant correlation between overall LEP promoter methylation rate and S-  
245 Leptin levels. Also, there was no correlation between overall LEP methylation and HQ scores.

246 According to Pearson's  $r$ , there was a negative correlation between mean methylation at CpG sites m349 ( $r = -$   
247  $0.473$ ,  $p = 0.023$ ) and m371 ( $r = - 0,462$ ,  $p = 0,026$ ) and HQ scores in subjects with PWS. No significant  
248 correlation was found for any other LEP CpG site shown to differ significantly between the groups in LEP  
249 methylation rate. The MLM showed no significant effect of the factor "clinical severity of hyperphagia" on the  
250 methylation rate ( $F_{(1,1076)} = 1.571$ ;  $p = 0.210$ ).

251

## 252 LEPR METHYLATION

253 MLM revealed significant fixed effects of factors group ( $F_{(1,813)} = 11,021$ ;  $p = 0.001$ ) as well as CpG-position  
254 ( $F_{(23,813)} = 8,984$ ;  $p < 0.001$ ) on the LEPR methylation rate. Overall LEPR mean methylation rate was lower in PWS  
255 with 3.0% compared to 4.4% in controls. In contrast to LEP analysis, we showed a significant group x CpG site  
256 interaction for LEPR gene ( $F_{(23,813)} = 2,414$ ;  $p < 0.001$ ). No significant fixed effects were seen for factor sex on  
257 methylation rate ( $p = 0.279$ ), nor for age ( $p = 0.977$ ) or BMI ( $p = 0.382$ ). Significance of group differences was  
258 not affected when age and gender were applied as additional factors.

259 Within the mixed linear model analysis split for single CpG sites, significant effects of factor group at eight  
260 individual CpG positions were seen (m211, m196, m86, m4, p31, p76, p88 and p129). No contiguous CpG  
261 positions could be identified. **Figure 4** shows a graphical representation of these results. For detailed statistical  
262 results see **Supplementary Material S4**.

263 Correlation analyses showed a highly significant inverse correlation between overall LEPR methylation rate and  
264 S-Leptin levels with Pearson's  $r = -0,120$ ,  $p < 0,001$ . No correlation was found between overall LEPR methylation  
265 rate and HQ scores. There were no correlations of individual CpG sites methylation rate with HQ scores.

266 The MLM showed no significant effect of the factor "clinical severity of hyperphagia" on the methylation rate ( $F$   
267  $_{(1,503)} = 0.018$ ;  $p = 0.893$ ).

268

## 269 **DISCUSSION**

270 The present study investigates serum leptin levels and methylation of the LEP and LEPR promoter in adult PWS  
271 compared to healthy BMI-matched controls. Our study reveals that PWS subjects have significantly higher S-  
272 leptin levels than controls while showing significantly downregulated LEP and LEPR promoter methylation.  
273 LEPR, but not LEP methylation correlated with S-leptin levels, while overall there was no correlation with the  
274 behavioral dimension in terms of the HQ-scores.

275

276 To our knowledge, the study is the first to demonstrate a significant difference in serum leptin levels between  
277 obese adults with PWS and weight-matched controls, a finding previously shown only for infants <6 years of  
278 age that appeared to resolve with increasing age. In line with previous studies a correlation of leptin level with  
279 BMI was still observed in both PWS and control group in the present study, but as they were matched for BMI  
280 both the PWS and control group were only slightly overweight at 27.2 respective 26.6  $\text{kg}/\text{m}^2$ . The mean BMI of  
281 our study seems to be considerably lower compared to other studies on the topic, for example, 37.2  $\text{kg}/\text{m}^2$  in  
282 Butler et al. or 41.2  $\text{kg}/\text{m}^2$  in Pagano et al. (19,20). Altogether, a BMI-independent effect of the factor PWS on  
283 S-leptin levels can be assumed. The comparatively high number of male subjects in our study might have a  
284 confounding effect, especially since sex-dependent differences in leptin regulation are known. An indication  
285 could be the study by Butler et al., which showed comparatively higher leptin blood levels only in male PWS  
286 subjects, who, unlike in our study, were non-obese (20). But this idea again conflicts with previous findings that  
287 women generally have higher leptin levels than men. In contrast, Kennedy et al. also showed no differences in

288 leptin levels between PWS and overweight controls, although females significantly predominated in the PWS  
289 cohort (18). Our results displayed no significant differences between the sexes in terms of blood leptin levels.

290

291 Furthermore, the present study is the first to investigate the epigenetic regulation of the satiety hormone  
292 leptin in people with PWS. In terms of obesity in general the majority of previous human studies have  
293 demonstrated an association between decreased LEP methylation levels and elevated leptin serum levels in  
294 obese subjects, hence an inverse correlation between LEP promoter methylation and leptin expression was  
295 assumed. Our results appear partly conclusive on this point from a neurobiological perspective, although it  
296 should be mentioned that no significant correlation was shown between LEP promoter methylation and S-  
297 leptin levels. Also, Lindgren et al. found no difference in leptin mRNA levels between PWS and obese controls,  
298 although increased leptin protein biosynthesis might be expected with decreased LEP promoter methylation as  
299 found in the present cohort (21). Also, data from our laboratory regarding LEP promoter methylation after  
300 bariatric surgery recently indicated decreased LEP promoter methylation with concomitant decreased serum  
301 leptin after surgically induced weight loss, contrary to the majority of observations made before (26). Overall,  
302 however, intervention-induced weight loss with the accompanying hormonal disruptions appears to bear little  
303 resemblance to the given conditions in PWS. In contrast, analogous to the study by Wilhelm et al, we also see  
304 an inverse correlation between LEPR methylation and S-leptin levels in the present cohort. Taken together, the  
305 findings of hypomethylated LEP/LEPR promoter and elevated S-leptin made in our PWS cohort mirror those  
306 previously made in obesity in general.

307 With central leptin resistance known to occur in obesity and suspected in PWS, a previous study suggested that  
308 above a count of 25-30ng/ml S-leptin central leptin resistance can be assumed (32), a limit which is exceeded  
309 by our PWS cohort. Given the abovementioned similarities of our findings in PWS to obesity in general, could  
310 PWS even serve as a model disease for leptin resistance?

311

312 The following hypothesis appears to emerge from the evidence to date. Among the chromosomal region  
313 affected in PWS is the melanoma antigen gene family member L2 (MAGEL2) gene. It is known that leptin-  
314 mediated activation of anorexigenic POMC neurons in the arcuate nucleus of the hypothalamus is mediated via  
315 leptin receptors LepRb. Leptin-induced POMC-activation was absent in a Magel2 knockout mouse model,  
316 suggesting that MAGEL2 is required for the leptin-mediated responses that is critical for POMC neuron-

317 mediated suppression of food intake (33). To that end, it can be hypothesized that loss of Magel2 disrupts the  
318 normal balance of LepR cell surface expression, because MAGEL2 and Necdin, another gene encoded in the  
319 PWS region, regulate the linkage of leptin receptors to an ubiquitination complex relevant for surface  
320 expression, internalization, and degradation processes. In contrast, while MAGEL2 is normally associated with  
321 cell surface abundance of LepR and its reduced degradation, the hypothalamus of Magel2-null mice showed  
322 less LepR and altered levels of proteins of the ubiquitin pathway that regulate LepR processing (34).  
323 Hypothalamic LepRbs are generally suspected to be involved in the development of leptin resistance.  
324 Downregulation of LepRb mRNA and proteins and impaired transport of LepRb to the plasma membrane in  
325 neuronal subpopulations of hypothalamic nuclei that control energy homeostasis have emerged as possible  
326 molecular mechanisms of leptin resistance before (35). Limited by the fact that we only investigated in  
327 peripheral blood DNA-methylation, our observation of significantly elevated serum leptin levels with decreased  
328 LEP and LEPR promoter methylation could represent a counter regulatory mechanism in response to leptin  
329 resistance in PWS genetically determined by MAGEL2 and Necdin derived downregulated LepRb expression in  
330 the hypothalamus satiety center. We hypothesize that central leptin resistance is counteracted by upregulated  
331 leptin hormone and leptin receptor expression in PWS mediated at the epigenetic level via decreased promoter  
332 methylation of LEP and LEPR, as we have seen analogously in previous studies on human obesity showing an  
333 inverse correlation between LEPR methylation and LepRb expression, for example (27). We see corroboration  
334 of our theory by our observation that LEPR, but not LEP promoter methylation, correlated significantly with S-  
335 leptin levels in the subjects, suggesting a functional regulatory link for LEPR. However, it remains to be  
336 mentioned that Wijesuriya et al. also noted that Magel2 mutation rodent models showed an overall less  
337 pronounced hyperphagia phenotype than other models, for example compared to Snord116 gene deficiency.  
338  
339 Likewise, our study failed to provide a conclusive link between laboratory findings and the behavioral  
340 dimension. Overall, no correlation of serum leptin levels with HQ scores was demonstrated in the PWS  
341 subjects. Also, no correlation was found between overall methylation rate of LEP and LEPR with HQ-scores in  
342 PWS, however solely for LEP CpG sites m349 and m371. From a neurobiological perspective, our finding that  
343 the methylation rates of the abovementioned CpG sites correlate negatively with the outcome of the  
344 hyperphagia questionnaire appears inconclusive. As stated above, it should be assumed that increased leptin  
345 expression via decreased LEP methylation should be accompanied by an increased feeling of satiety and,

346 accordingly, by decreased food-seeking behavior, which would correspond to a lower score on the HQ. In this  
347 respect, the correlations found seem most likely to be incidental. To this end, our findings appear to be in line  
348 with previous human studies on this topic like Goldstone et al. being unable to establish a connection between  
349 hormonal abnormalities in PWS and the behavioral dimension in the sense of an altered eating behavior (14).  
350 In synopsis of our and previous findings, no connection between leptin regulation and behavioral abnormalities  
351 in PWS can be assumed.

352

### 353 LIMITATIONS

354 Overall, the cohort size of our study is small, but in line with that of previous studies on the topic.  
355 Especially limiting appears the use of peripheral blood material, although the regulation of satiety is essentially  
356 due to central processes. Therefore, only indirect conclusions can be drawn regarding the central processes  
357 behind leptin resistance in PWS. Unfortunately, we did not have central material such as CSF available for our  
358 study, as such sampling is hardly justifiable from an ethical point of view.  
359 Furthermore, the HQ currently is described to be the gold standard for assessing food-seeking behavior in PWS.  
360 However, the overall data on the validity of the questionnaire appears limited. In general, it offers only an  
361 indirect assessment, since it is completed by relatives or caregivers, which could be subject to perceptual bias  
362 compared to the PWS individuals themselves. Also, the HQ was not performed in the control subjects, so  
363 comparability is not given.

364 Another crucial limitation of the study seems to be the use of BMI as determinant of obesity in the subjects.  
365 BMI values of the control group could likely be confounded by a comparatively increased muscle mass. Body fat  
366 percentage could be the much more accurate determinant for comparison at this point, especially since leptin  
367 is primarily produced in adipocytes. However, the comparability with previous studies still appears to be given  
368 insofar as these also mostly used body weight or BMI as assessment standard.

369 Furthermore, our study lacks a healthy, normal-weight control group for comparisons regarding leptin  
370 resistance in obese and non-obese subjects.

371

### 372 CONCLUSION

373 The observed differences in leptin expression again pointed towards a dysregulation of the hormonal network  
374 regulating hunger and satiety in people with PWS without being able to provide a detectable connection of

375 leptin dysregulation and food-seeking behavior typical in PWS. But overall, our research findings strengthen the  
376 hypothesis that PWS could be considered as a model disease for leptin resistance and thus be of great interest  
377 for obesity research in general.

378

#### 379 **CONFLICTS OF INTEREST**

380 All authors declare to have no conflicts of interest.

381

#### 382 **AUTHOR CONTRIBUTION**

383 Jelte Wieting contributed in acquisition of samples, drafted the manuscript and contributed to analysis and  
384 interpretation of data. Kirsten Jahn carried out the experiments and contributed to analysis and interpretation  
385 of data. Vanessa Buchholz and Ralf Lichtinghagen carried out the experiments. Christian K. Eberlein contributed  
386 to acquisition of samples and contributed to interpretation of data and revised the manuscript critically for  
387 important intellectual content. Stefan Bleich contributed to interpretation of data and revised the manuscript  
388 critically for important intellectual content. Maximilian Deest contributed to acquisition of samples, analysis,  
389 and interpretation of the data and was substantially involved in drafting the manuscript. Helge Frieling  
390 contributed to conception and design of the study, interpretation of data, and revised the manuscript critically  
391 for important intellectual content.

392

#### 393 **REFERENCES**

- 394 1. Lioni T, Reid SM, White SM, Rowell MM. A population-based profile of 160 Australians with Prader-  
395 Willi syndrome: Trends in diagnosis, birth prevalence and birth characteristics. *Am J Med Genet Part A*.  
396 2015;
- 397 2. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: A review of clinical, genetic, and  
398 endocrine findings. *J Endocrinol Invest*. 2015;
- 399 3. Muscogiuri G, Formoso G, Pugliese G, Ruggeri RM, Scarano E, Colao A. Prader- Willi syndrome: An  
400 uptodate on endocrine and metabolic complications. *Reviews in Endocrine and Metabolic Disorders*.  
401 2019.
- 402 4. Dykens E, Shah B. Psychiatric disorders in Prader-Willi syndrome: Epidemiology and management. *CNS*  
403 *Drugs*. 2003.

- 404 5. Proffitt J, Osann K, McManus B, Kimonis VE, Heinemann J, Butler MG, et al. Contributing factors of  
405 mortality in Prader–Willi syndrome. *Am J Med Genet Part A* [Internet]. 2019 Feb 1 [cited 2021 Aug  
406 20];179(2):196–205. Available from: <https://pubmed.ncbi.nlm.nih.gov/30569567/>
- 407 6. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative Review: The Role of Leptin in Human  
408 Physiology: Emerging Clinical Applications. *Ann Intern Med* [Internet]. 2010 Jan 19 [cited 2021 Aug  
409 21];152(2):93. Available from: [/pmc/articles/PMC2829242/](https://pubmed.ncbi.nlm.nih.gov/19350671/)
- 410 7. Scott MM, Lachey JL, Sternson SM, Lee CE, Elias CF, Friedman JM, et al. Leptin targets in the mouse  
411 brain. *J Comp Neurol* [Internet]. 2009 Jun 10 [cited 2021 Aug 24];514(5):518–32. Available from:  
412 <https://pubmed.ncbi.nlm.nih.gov/19350671/>
- 413 8. Morash B, Li A, Murphy PR, Wilkinson M, Ur E. Leptin gene expression in the brain and pituitary gland.  
414 *Endocrinology* [Internet]. 1999 [cited 2021 Aug 24];140(12):5995–8. Available from:  
415 <https://pubmed.ncbi.nlm.nih.gov/10579368/>
- 416 9. Considine R V., Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum  
417 Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans. *N Engl J Med* [Internet].  
418 1996 Feb [cited 2021 Aug 24];334(5):292–5. Available from:  
419 <https://pubmed.ncbi.nlm.nih.gov/8532024/>
- 420 10. Ostlund RE, Yang JW, Klein S, Gingerich R. Relation between plasma leptin concentration and body fat,  
421 gender, diet, age, and metabolic covariates. *J Clin Endocrinol Metab* [Internet]. 1996 Nov [cited 2021  
422 Aug 24];81(11):3909–13. Available from: <https://pubmed.ncbi.nlm.nih.gov/8923837/>
- 423 11. Kolaczynski JW, Considine R V., Ohannesian J, Marco C, Opentanova I, Nyce MR, et al. Responses of  
424 leptin to short-term fasting and refeeding in humans: A link with ketogenesis but not ketones  
425 themselves. *Diabetes* [Internet]. 1996 [cited 2021 Aug 24];45(11):1511–5. Available from:  
426 <https://pubmed.ncbi.nlm.nih.gov/8866554/>
- 427 12. Korbonits M, Trainer PJ, Little JA, Edwards R, Kopelman PG, Besser GM, et al. Leptin levels do not  
428 change acutely with food administration in normal or obese subjects, but are negatively correlated with  
429 pituitary-adrenal activity. *Clin Endocrinol (Oxf)* [Internet]. 1997 [cited 2021 Aug 24];46(6):751–7.  
430 Available from: <https://pubmed.ncbi.nlm.nih.gov/9274707/>
- 431 13. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and  
432 body weight in humans: A review [Internet]. Vol. 8, *Obesity Reviews*. *Obes Rev*; 2007 [cited 2021 Aug

- 433 24]. p. 21–34. Available from: <https://pubmed.ncbi.nlm.nih.gov/17212793/>
- 434 14. Goldstone AP, Holland AJ, Butler J V., Whittington JE. Appetite hormones and the transition to  
435 hyperphagia in children with Prader-Willi syndrome. *Int J Obes* [Internet]. 2012 Dec [cited 2021 Aug  
436 21];36(12):1564–70. Available from: <https://pubmed.ncbi.nlm.nih.gov/22270375/>
- 437 15. Haqq AM, Grambow SC, Muehlbauer M, Newgard CB, Svetkey LP, Carrel AL, et al. Ghrelin  
438 concentrations in Prader-Willi syndrome (PWS) infants and children: changes during development. *Clin  
439 Endocrinol (Oxf)* [Internet]. 2008 Dec [cited 2021 Aug 21];69(6):911. Available from:  
440 </pmc/articles/PMC2614621/>
- 441 16. Orsso CE, Butler AA, Muehlbauer MJ, Cui HN, Rubin DA, Pakseresht M, et al. Obestatin and adropin in  
442 Prader-Willi syndrome and nonsyndromic obesity: Associations with weight, BMI-z, and HOMA-IR.  
443 *Pediatr Obes* [Internet]. 2019 May 1 [cited 2021 Aug 21];14(5):e12493. Available from:  
444 </pmc/articles/PMC7456601/>
- 445 17. Hirsch HJ, Gross I, Pollak Y, Eldar-Geva T, Gross-Tsur V. Irisin and the Metabolic Phenotype of Adults  
446 with Prader-Willi Syndrome. *PLoS One* [Internet]. 2015 Sep 3 [cited 2021 Aug 21];10(9). Available from:  
447 </pmc/articles/PMC4559418/>
- 448 18. Kennedy L, Bittel D, Kibiryeveva N, Kalra S, Torto R, Butler M. Circulating adiponectin levels, body  
449 composition and obesity-related variables in Prader-Willi syndrome: comparison with obese subjects.  
450 *Int J Obes (Lond)* [Internet]. 2006 Feb [cited 2021 Aug 21];30(2):382. Available from:  
451 </pmc/articles/PMC6704478/>
- 452 19. Pagano C, Marin O, Calcagno A, Schiappelli P, Pilon C, Milan G, et al. Increased serum resistin in adults  
453 with Prader-Willi syndrome is related to obesity and not to insulin resistance. *J Clin Endocrinol Metab*  
454 [Internet]. 2005 Jul [cited 2021 Aug 21];90(7):4335–40. Available from:  
455 <https://pubmed.ncbi.nlm.nih.gov/15870134/>
- 456 20. Butler MG, Moore J, Morawiecki A, Nicolson M. Comparison of Leptin Protein Levels in Prader-Willi  
457 Syndrome and Control Individuals. *Am J Med Genet* [Internet]. 1998 Jan 6 [cited 2021 Aug 20];75(1):7.  
458 Available from: </pmc/articles/PMC6775636/>
- 459 21. Lindgren AC, Marcus C, Skwirut C, Elimam A, Hagenas L, Schalling M, et al. Increased leptin messenger  
460 RNA and serum leptin levels in children with Prader-Willi syndrome and nonsyndromal obesity. *Pediatr  
461 Res* [Internet]. 1997 [cited 2021 Aug 21];42(5):593–6. Available from:



- 462 <https://pubmed.ncbi.nlm.nih.gov/9357929/>
- 463 22. Bird A. DNA methylation patterns and epigenetic memory [Internet]. Vol. 16, *Genes and Development*.  
464 *Genes Dev*; 2002 [cited 2021 Aug 25]. p. 6–21. Available from:  
465 <https://pubmed.ncbi.nlm.nih.gov/11782440/>
- 466 23. Dunstan J, Bressler JP, Moran TH, Pollak JS, Hirsch AG, Bailey-Davis L, et al. Associations of LEP, CRH,  
467 ICAM-1, and LINE-1 methylation, measured in saliva, with waist circumference, body mass index, and  
468 percent body fat in mid-childhood. *Clin Epigenetics* [Internet]. 2017 Mar 29 [cited 2021 Aug 24];9(1).  
469 Available from: <https://pubmed.ncbi.nlm.nih.gov/28360946/>
- 470 24. García-Cardona MC, Huang F, García-Vivas JM, López-Camarillo C, Del Río Navarro BE, Navarro Olivos E,  
471 et al. DNA methylation of leptin and adiponectin promoters in children is reduced by the combined  
472 presence of obesity and insulin resistance. *Int J Obes* [Internet]. 2014 Nov 13 [cited 2021 Aug  
473 24];38(11):1457–65. Available from: <https://pubmed.ncbi.nlm.nih.gov/24549138/>
- 474 25. Melzner I, Scott V, Dorsch K, Fischer P, Wabitsch M, Brüderlein S, et al. Leptin gene expression in  
475 human preadipocytes is switched on by maturation-induced demethylation of distinct CpGs in its  
476 proximal promoter. *J Biol Chem* [Internet]. 2002 Nov 22 [cited 2021 Aug 24];277(47):45420–7. Available  
477 from: <https://pubmed.ncbi.nlm.nih.gov/12213831/>
- 478 26. Wilhelm J, Birkenstock A, Buchholz V, Müller A, Aly SA, Gruner-Labitzke K, et al. Promoter Methylation  
479 of LEP and LEPR before and after Bariatric Surgery: A Cross-Sectional Study. *Obes Facts* [Internet]. 2021  
480 Mar 1 [cited 2021 Sep 20];14(1):93–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/33530087/>
- 481 27. Chavira-Suárez E, Ramírez-Mendieta AJ, Martínez-Gutiérrez S, Zárate-Segura P, Beltrán-Montoya J,  
482 Espinosa-Maldonado NC, et al. Influence of pre-pregnancy body mass index (p-BMI) and gestational  
483 weight gain (GWG) on DNA methylation and protein expression of obesogenic genes in umbilical vein.  
484 *PLoS One* [Internet]. 2019 Dec 1 [cited 2021 Nov 24];14(12). Available from:  
485 <https://pubmed.ncbi.nlm.nih.gov/31794592/>
- 486 28. Deest M, Jakob MM, Seifert J, Bleich S, Frieling H, Eberlein C. Sertraline as a treatment option for  
487 temper outbursts in Prader–Willi syndrome. *Am J Med Genet Part A*. 2020;
- 488 29. Deest M, Buchholz V, Jahn K, Eberlein C, Bleich S, Frieling H. Hypomethylation of monoamine oxidase A  
489 promoter/exon 1 region is associated with temper outbursts in Prader-Willi syndrome. *J Psychiatr Res*.  
490 2021 Nov 9;

- 491 30. Fehnel SE, Brown TM, Nelson L, Chen A, Kim DD, Roof E, et al. Development Of The Hyperphagia  
492 Questionnaire For Use In Prader-Willi Syndrome Clinical Trials. *Value Heal* [Internet]. 2015 May 1 [cited  
493 2021 Aug 9];18(3):A25. Available from:  
494 <http://www.valueinhealthjournal.com/article/S1098301515002119/fulltext>
- 495 31. Lewin J, Schmitt AO, Adorján P, Hildmann T, Piepenbrock C. Quantitative DNA methylation analysis  
496 based on four-dye trace data from direct sequencing of PCR amplicates. *Bioinformatics* [Internet].  
497 2004 Nov 22 [cited 2021 Aug 9];20(17):3005–12. Available from:  
498 <https://pubmed.ncbi.nlm.nih.gov/15247106/>
- 499 32. Holtkamp K, Hebebrand J, Mika C, Heer M, Heussen N, Herpertz-Dahlmann B. High serum leptin levels  
500 subsequent to weight gain predict renewed weight loss in patients with anorexia nervosa.  
501 *Psychoneuroendocrinology* [Internet]. 2004 Jul [cited 2021 Nov 22];29(6):791–7. Available from:  
502 <https://pubmed.ncbi.nlm.nih.gov/15110928/>
- 503 33. Hill JW, Williams KW, Ye C, Luo J, Balthasar N, Coppari R, et al. Acute effects of leptin require PI3K  
504 signaling in hypothalamic proopiomelanocortin neurons in mice. *J Clin Invest* [Internet]. 2008 May 1  
505 [cited 2021 Nov 23];118(5):1796–805. Available from: <https://pubmed.ncbi.nlm.nih.gov/18382766/>
- 506 34. Wijesuriya TM, De Ceuninck L, Masschaele D, Sanderson MR, Carias KV, Tavernier J, et al. The Prader-  
507 Willi syndrome proteins MAGEL2 and necdin regulate leptin receptor cell surface abundance through  
508 ubiquitination pathways. *Hum Mol Genet* [Internet]. 2017 Nov 1 [cited 2021 Aug 25];26(21):4215–30.  
509 Available from: <https://pubmed.ncbi.nlm.nih.gov/28973533/>
- 510 35. Genchi VA, D’oria R, Palma G, Caccioppoli C, Cignarelli A, Natalicchio A, et al. Impaired Leptin Signalling  
511 in Obesity: Is Leptin a New Thermolipokine? *Int J Mol Sci* [Internet]. 2021 Jun 2 [cited 2021 Nov  
512 22];22(12). Available from: [/pmc/articles/PMC8235268/](https://pubmed.ncbi.nlm.nih.gov/35235268/)
- 513

## Figures




Figure 1 Chart showing significant higher mean S-Leptin (with SD) in PWS compared to BMI-matched controls




Figure 2 Chart showing significant lower mean LEP and LEPR promoter methylation (with SD) in PWS compared to BMI-matched controls





Figure 3 Chart revealing significant lower mean methylation of LEP-promoter (with SD) in eleven of partially contiguous CpG regions in PWS compared to controls (only shown CpG sites with a significant difference)



**Figure 4** Chart revealing significant difference in mean methylation of LEPR-promoter (with SD) in eight CpG regions in comparison of PWS and controls (only shown CpG sites with a significant difference)

## Tables

	<b>PWS</b>	<b>Control</b>					
<b>n=</b>	24	13					
<b>Sex</b>	14 male (58.3%), 10 female (41.7%)	8 male (61.5%), 5 female (38.5%)					
<b>Subtype</b>	11 DelPWS	7 UPD	2 IC	4 UPD/IC			

	<b>Mean Age (in y)</b>	<b>Min</b>	<b>Max</b>	<b>SD</b>	<b>Mann-Whitney-U-test</b>		
					<b>U</b>	<b>Z</b>	<b>p</b>
<b>PWS</b>	27	12	55	12.044	107	1.561	0.124
<b>control</b>	32	18	47	8.140			

	<b>Mean BMI (kg/m<sup>2</sup>)</b>						
<b>PWS</b>	27.20	19.100	39.111	5.793	166	0.318	0.766
<b>control</b>	26.60	19.370	40.009	5.467			

	<b>Mean S-leptin (ng/ml)</b>						
<b>PWS</b>	32.747	3.261	79.822	24.018	245.000	2.831	0.004*
<b>control</b>	11.928	0.116	43.797	12.788			

**Table 1** Demographics of PWS and control cohort